The effect of the use of Mexidol during the "therapeutic window" of ischemic stroke on the effectiveness of intravenous thrombolytic therapy

Authors:
K.S. KNNI, T.V. DEMIN, L.B. ADEEVA

GAUZ "Interregional Clinical and Diagnostic Center", Kazan, Russia

Place of publication:
“NEUROLOGY, NEUROPSYCHIATRY, PSYCHOSOMATICS”, 2018;10(3):86–90

Abstract:
The aim of the study was to evaluate the effect of intravenous mexidol administration during the "therapeutic window" on the effectiveness of intravenous thrombolytic therapy (TLT). Patients and methods. The retrospective study included 123 patients with ischemic stroke (IS) who underwent intravenous TLT in the vascular centers of the Republic of Tatarstan. To assess the dynamics of the neurological status, the National Institutes of Health Stroke Scale (NIHSS) was used. Depending on the initial severity of neurological deficit, all patients were divided into three subgroups: with mild IS (MI) and an NIHSS score of <8 points upon admission Results. The use of mexidol at the prehospital stage followed by thrombolytic therapy in patients with ischemic stroke has a positive effect on the regression of neurological deficit, regardless of the severity of the disease. Significant differences were found in the degree of regression of neurological deficit according to NIHSS 24 hours and 10 days after admission in patients with ischemic stroke who were administered mexidol at the prehospital stage and who did not receive this drug before thrombolytic therapy. The use of mexidol before thrombolytic therapy contributes to greater regression of neurological deficit. A lower incidence of hemorrhagic transformations was found in patients who received mexidol at the prehospital stage compared to patients who did not use this drug. Conclusion. The obtained data demonstrate a positive effect of mexidol on the efficacy and safety of thrombolytic therapy in patients with ischemic stroke. Key words: ethyl methylhydroxypyridine succinate; intravenous thrombolytic therapy; ischemic stroke; neuroprotective therapy.